DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,736,810 | +14.3% | 99,705 | +10.6% | 4.68% | +19.7% |
| Q2 2023 | $21,636,000 | -4.8% | 90,150 | 0.0% | 3.91% | -10.3% |
| Q1 2023 | $22,721,406 | +11.5% | 90,150 | +17.4% | 4.36% | -5.1% |
| Q4 2022 | $20,381,602 | -1.9% | 76,790 | -4.5% | 4.59% | -21.0% |
| Q3 2022 | $20,772,000 | +1.9% | 80,420 | 0.0% | 5.81% | +27.3% |
| Q2 2022 | $20,388,000 | -15.3% | 80,420 | -2.0% | 4.57% | +2.0% |
| Q1 2022 | $24,059,000 | -10.8% | 82,020 | 0.0% | 4.48% | -4.2% |
| Q4 2021 | $26,985,000 | +6.0% | 82,020 | -1.9% | 4.67% | +4.3% |
| Q3 2021 | $25,460,000 | +7.9% | 83,630 | -4.9% | 4.48% | +15.1% |
| Q2 2021 | $23,589,000 | +19.7% | 87,900 | +0.4% | 3.89% | +14.4% |
| Q1 2021 | $19,715,000 | +7.1% | 87,590 | +5.7% | 3.40% | +0.5% |
| Q4 2020 | $18,400,000 | +33.7% | 82,830 | +29.6% | 3.39% | +1.3% |
| Q3 2020 | $13,760,000 | +21.5% | 63,900 | -0.2% | 3.34% | +6.6% |
| Q2 2020 | $11,326,000 | +9.2% | 64,050 | -14.5% | 3.13% | +20.3% |
| Q1 2020 | $10,374,000 | – | 74,950 | – | 2.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |